지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 340 - 348 (9page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Ustekinumab is effective in active Crohn’s disease. In a retrospective study, we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not always reflect the average “real world” patient cohort, we assessed weather patients who would not have qualified for approval studies show similar outcomes. Methods: Forty-one patients with mild to severe active Crohn’s disease were treated with ustekinumab (intravenous 6 mg per kg/body weight) followed by subcutaneous ustekinumab (90 mg) at week 8. Depending on the clinical response maintenance therapy was chosen every 8 or 12 weeks. Clinical response was defined by Crohn’s Disease Activity Index (CDAI) decline, decline of stool frequency or clinical improvement. Inclusion criteria for approval studies were assessed. Results: The 58.5% (24/41) showed clinical response to ustekinumab. The 58.3% of this group (14/24) achieved clinical remission. Clinical response correlated significantly with drop of stool frequency and improvement of CDAI score. The 39 out of 41 patients had no side effects and we observed no serious infections. About a third of our patients would not have met ustekinumab approval study criteria. However, patients who did not meet study criteria showed clinical improvement numerically in the same range compared to patients who would have qualified for approval studies. Conclusions: Ustekinumab is effective, safe and well tolerated in a highly therapy refractory patient cohort. Even though a reasonable number of patients did not meet ustekinumab approval study criteria, approval study results seem to be representative to the overall patient cohort.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
Intestinal research
2021 .01
-
Oral Symptoms Related to Vitamin B12 Deficiency in a Patient with Crohn’s Disease
Journal of Oral Medicine and Pain
2018 .12
-
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Intestinal research
2023 .01
-
Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
Gut and Liver
2016 .01
-
Dietary Therapies for Management of Crohn’s Disease
대한외과학회 학술대회 초록집
2022 .11
-
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies
Intestinal research
2017 .01
-
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Journal of Korean Medical Science
2022 .04
-
Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
Intestinal research
2020 .01
-
Nutrition Management of Crohn’s Disease Patients with Surgical Complications
대한외과학회 학술대회 초록집
2022 .11
-
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Intestinal research
2022 .07
-
Role of Smoking as a Risk Factor in East Asian Patients with Crohn's Disease
Gut and Liver
2017 .01
-
Erratum : Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Intestinal research
2023 .04
-
크론병 환자의 삶의 질 모형
기본간호학회지
2020 .11
-
Impact of Sarcopenia on the Postoperative Outcome and Recurrence in the Patients With Crohn’s Disease
대한외과학회 학술대회 초록집
2021 .11
-
Response: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study
Diabetes and Metabolism Journal
2020 .01
-
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Intestinal research
2021 .10
-
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Intestinal research
2024 .07
-
한방치료로 관해가 유도된 소아 크론병 환자의 증례 보고
대한한방내과학회지
2021 .10
-
Radiologic images of complications of Crohn's disease
International Journal of Gastrointestinal Intervention
2023 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0